Pharmaceutical composition for treatment of diseases caused by IL-6 production

• US 20070036785A1
• Filed: 10/24/2006
• Published: 02/15/2007
• Est. Priority Date: 10/21/1994
• Status: Abandoned Application

• Current Assignee: Asao Katsume, Hiroyuki Saito, Tadamitsu Kishimoto
• Original Assignee: Asao Katsume, Hiroyuki Saito, Tadamitsu Kishimoto
• Inventors: Kishimoto, Tadamitsu, Saito, Hiroyuki, Katsume, Asao
• Application Number:
  US11/585,172
• Publication Number:
  US 20070036785A1
• Time in Patent Office: Days
• US Class Current: 424/143.100
• CPC Class Codes: A01K 2217/05 Animals comprising random inserted nucleic acids (transgenic)
• CPC Class Codes: A01K 2227/105 Murine
• CPC Class Codes: A01K 2267/01 Animal expressing industrially exogenous proteins
• CPC Class Codes: A01K 67/0275 Genetically modified vertebrates, e.g. transgenic
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/04 Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• CPC Class Codes: A61P 7/06 Antianaemics
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2319/00 : Fusion polypeptide
• CPC Class Codes: C12N 15/8509 : for producing genetically modified animals, e.g. transgenic

Abstract

Pharmaceutical compositions for prevention or treatment of diseases caused by interleukin-6 production, comprising an antibody to interleukin-6 receptor (IL-6R antibody). As the IL-6R antibody, an antibody of animals other than the human such as mice, rats, etc., a chimeric antibody between these and a human antibody, a reshaped human antibody, etc. may be used. The pharmaceutical compositions are useful for prevention or treatment of diseases caused by interleukin-6 production such as plasmacytosis, anti-IgGl-emia, anemia, nephritis, etc.

Claims

1. A method of treating a subject having a disease caused by interleukin-6 (IL-6) production comprising administering to said subject a therapeutically effective amount of an antibody to an IL-6 receptor (IL-6R) in a pharmaceutically acceptable carrier.

2. A method according to claims 1, wherein said disease is plasmacytosis.

3. A method according to claim 2, wherein said plasmacytosis is induced by rheumatism.

4. A method according to claim 2, wherein said plasmacytosis is induced by Castleman'"'"'s disease.

5. A method according to claim 1, wherein said disease is hyperimmunoglobulinemia.

6. A method according to claim 1, wherein said disease is anemia.

7. A method according to claim 1, wherein said disease is nephritis.

8. A method according to claim 7, wherein said nephritis is mesangium proliferative nephritis.

9. A method according claim 1, wherein said antibody is a monoclonal antibody.

10. A method according to claim 9, wherein said monoclonal antibody is the PM-1 antibody produced by hybridoma PM-1, accession number FERM BP-2998.

11. A method according to claim 9, wherein said monoclonal antibody is a chimeric antibody comprising the variable immunoglobulin heavy and light chains from a murine monoclonal antibody to an IL-6 receptor (IL-6R) and the constant immunoglobulin heavy and light chains from a human monoclonal antibody.

12. A method according to claim 9, wherein said monoclonal antibody is a humanized murine monoclonal antibody to an IL-6 receptor (IL-6R).

13. A method according to claim 12, wherein said humanized murine monoclonal antibody to an IL-6 receptor (IL-6R) is a humanized PM-1 antibody, wherein the PM-1 antibody to humanization is produced by hybridoma PM-1, accession number FERM BP-2998.

14. A method according claim 1, wherein said antibody is a chimeric antibody.

15. A method of preventing a disease in a subject, wherein the disease is caused by interleukin-6 (IL-6) production, comprising administering to said subject an antibody to an IL-6 receptor (IL-6R) in a pharmaceutically acceptable carrier.